Advertisement
Advertisement
LEGN
Legend Biotech Corporation - ADR
18.76
USDSponsored
-0.29
-1.50%
Mar 13, 15:59 UTC -4
Closed
After-Market
18.71
-0.06
-0.31%
LEGN Earnings Reports
Positive Surprise Ratio
LEGN beat 10 of 21 last estimates.
48%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$316.36M
/-$0.07
Implied change from Q4 25 (Revenue/ EPS)
+3.28%
/-12.50%
Implied change from Q1 25 (Revenue/ EPS)
+62.19%
/-87.04%
Legend Biotech Corporation - ADR earnings per share and revenue
On Mar 10, 2026, LEGN reported earnings of -0.08 USD per share (EPS) for Q4 25, beating the estimate of -0.11 USD, resulting in a 27.73% surprise. Revenue reached 306.30 million, compared to an expected 313.01 million, with a -2.14% difference. The market reacted with a +2.19% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 316.36 million USD, implying an decrease of -12.50% EPS, and increase of 3.28% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Mineralys Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.40
Surprise
+26.40%
Corvus Pharmaceuticals, Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.15
Surprise
-13.72%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.00
Actual
$0.01
Surprise
+16.28%
ADC Therapeutics SA
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.04
Surprise
+85.39%
Kamada Ltd
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.07
Actual
$0.06
Surprise
-24.15%
Allogene Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.22
Actual
-$0.17
Surprise
+22.73%
Molecular Partners AG - ADR
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.32
Surprise
+7.09%
Whitehawk Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.15
Actual
-$0.34
Surprise
-116.42%
Codexis, Inc.
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.04
Actual
$0.11
Surprise
+357.01%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
FAQ
What were Legend Biotech Corporation - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Legend Biotech Corporation - ADR reported EPS of -$0.08, beating estimates by 27.73%, and revenue of $306.30M, -2.14% below expectations.
How did the market react to Legend Biotech Corporation - ADR's Q4 2025 earnings?
The stock price moved up 2.19%, changed from $19.14 before the earnings release to $19.56 the day after.
When is Legend Biotech Corporation - ADR expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Legend Biotech Corporation - ADR's next earnings report?
Based on 7
analysts, Legend Biotech Corporation - ADR is expected to report EPS of -$0.07 and revenue of $316.36M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement